Allievex, backed by Pappas and Novo, scoops up BioMarin ultra-rare disease assets

Why Pappas created Allievex to shepherd an MPS IIIB program and other ultra-orphan assets

Pappas Ventures has founded Allievex to house a portfolio of rare disease candidates deprioritized by BioMarin, including a therapy for mucopolysaccharidosis IIIB that has reached clinical testing.

Newly launched Allievex Corp. holds an exclusive, worldwide license from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to tralesinidase alfa (formerly BMN 250), an enzyme replacement therapy to treat MPS IIIB, also known as Sanfilippo type B syndrome. Now

Read the full 626 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE